Adagene Inc. business relationships
Companies named in Adagene Inc.’s 20-F filed 2026-04-01, and public companies whose annual reports name Adagene Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 47 / 100 Top 1% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Adagene Inc.’s annual report 8
“| | ● | | In July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology.” SEC filing
“Under the collaboration, Roche is sponsoring and conducting a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab.” SEC filing
“Previously, we have entered into technology licensing agreements with Sanofi and Exelixis to develop antibody-based therapeutics against tumor targets using our SAFEbody technology.” SEC filing
“| | ● | | In July 2025, we announced a clinical trial collaboration agreement with Sanofi to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ADG126 in combination with Sanofi's SAR445877 (PD-1 x IL-15 fusion protein) on adults with advanced solid tumors.” SEC filing
“In February 2021, we entered into a collaboration and license agreement (the "Exelixis Agreement") with Exelixis, Inc. ("Exelixis"), pursuant to which we agreed to generate masked antibodies with our SAFEbody technology against two targets selected by Exelixis.” SEC filing
“In April 2022, the Group entered in a letter agreement (the "Exelixis Letter Agreement") in reference to the Exelixis Agreement with Exelixis for expanded collaboration in SAFEbody discovery.” SEC filing
“In November 2025, we entered into a license agreement (the "Third Arc Agreement") with Third Arc Bio, Inc. ("Third Arc"), which we agreed to grant an exclusive license on a molecule specific license to Third Arc to use our SAFEbody technology for a masked CD3 for the research, development, manufactu...” SEC filing
“In July 2025, we entered into a license agreement (the "ConjugateBio Agreement") with ConjugateBio Inc. ("ConjugateBio"), pursuant to which we agreed to grant an exclusive license of our proprietary antibody to ConjugateBio.” SEC filing
Companies whose annual reports name Adagene Inc. 1
“• Adagene Inc., a company specializing in the discovery and development of antibody-based therapies (2022) : collaboration” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.